A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
INTRODUCTION: Recent pharmacological options for weight management include the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and liraglutide, and the glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist tirzepatide,…
INTRODUCTION: Obesity is a complex and chronic disease associated with complications including type 2 diabetes, cardiovascular disease, and malignancy. Although pharmacotherapy has emerged as an effective treatment option, the determinants of patient…
Several glucagon-like peptide-1 receptor agonists (GLP-1RAs) have proven their ability to reduce major adverse cardiovascular events (MACEs) among at-risk patients living with type 2 diabetes (T2D). Tirzepatide, a dual GIP/GLP-1 receptor agonist, dem…
BACKGROUND: Metabolic dysfunction (MetD) and alcohol use disorder (AUD) frequently coexist as synergistic risk factors for steatotic liver disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established therapies for MetD, including typ…
OBJECTIVES: Diabetes mellitus, including new-onset diabetes after transplant, is a prevalent complication in solid-organ transplant recipients, often necessitating complex glycemic management. Glucagon-like peptide-1 receptor agonists, including sema…
INTRODUCTION: Advances in type 2 diabetes (T2D) treatment have expanded therapeutic options, but evidence on optimal treatment sequencing for long-term outcomes remains limited. This study evaluated six common T2D treatment pathways in the US using l…
BACKGROUND: Type 2 diabetes (T2D) management has shifted towards integrated cardiometabolic and renal risk reduction. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) and newer dual agonists show promising benefits, comparative evidence…
OBJECTIVE: Adjunctive use of tirzepatide or semaglutide has demonstrated benefits in improving glucose control (HbA1c, Time in Range), reducing body weight, and insulin requirements, in overweight (OW) or obese (OB) adults with type 1 diabetes (T1D).…
Obesity is currently considered as adiposity based chronic disease with BMI as therapeutic target for prevention of obesity associated complications. For treatment of obesity, a stepwise approach is recommended including multifactorial basal therapy…
PURPOSE OF REVIEW: To synthesize current evidence supporting intentional weight reduction as a cardiometabolic strategy for treating and preventing heart failure (HF) across the ejection-fraction spectrum, examine the influence of baseline obesity on…
INTRODUCTION: Obesity and type 2 diabetes mellitus (Type 2 DM) are rising at an alarming rate among children and adolescents. This population often exhibits suboptimal glycemic control and diabetes-related complications. Glucagon-like peptide-1 recep…
BACKGROUND: Obesity-related heart failure with preserved ejection fraction (HFpEF) is associated with high morbidity and limited therapeutic options. Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like…
Pediatric obesity is increasing at an alarming rate, affecting over 381 million children worldwide and emerging as a critical public health issue. According to World Health Organization (WHO) 2016, 40% of adults are overweight and 13% are obese, high…
BACKGROUND: Obesity affects over 40% of US adults, with severe obesity on the rise. Despite recognition of obesity as a chronic disease, it remains underdiagnosed and undertreated. Access to evidence-based obesity treatment is limited, leading to inc…
OBJECTIVE: To evaluate the comparative effectiveness of dulaglutide or semaglutide versus tirzepatide on cardiovascular outcomes in adults with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). RESEARCH DESIGN AND METHODS: Two…
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists, including a dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonist, have expanded treatment options for overweight and obesity. However, real-world data within Medicaid pop…
BACKGROUND: Despite the clinical efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for weight loss, real-world persistence remains substantially lower than seen in clinical trials. Since 2021, GLP-1RA shortages and changes in product a…
Heart failure with preserved ejection fraction (HFpEF) affects 32 million people worldwide and is responsible for tens of billions of dollars in healthcare expenditure annually, with costs primarily driven by hospitalizations. HFpEF is notoriously di…
INTRODUCTION: Obesity poses an increasing threat to U.S. military readiness, with over half of active-duty service members classified as overweight and up to 27% with obesity. Within the Military Health System (MHS), obesity contributes to service di…